Valuation: Endonovo Therapeutics, Inc.

Market Cap 2.77M 2.43M 2.24M 2.09M 3.94M 262M 4.01M 26.88M 10.43M 129M 10.42M 10.19M 451M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.69M 8.02M 7.48M 14.1M 939M 14.35M 96.21M 37.35M 463M 37.29M 36.46M 1.61B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 2012-02-29
Investor Relations Contact - 2014-04-30
Corporate Officer/Principal 77 2022-11-29
Director TitleAgeSince
Chairman 61 2012-02-29
Change 5-day change 1-year change 3-year change Capi.($)
-9.62%-18.42% - - 1.81K
+3.31%+1.93%+69.29%+129.27% 55.78B
-1.32%+16.55%+89.14%+101.41% 55.66B
-1.28%+2.68%-12.60%-13.79% 23.84B
+1.79%+4.38%+5.94%+405.31% 22.7B
+4.45%+8.43%+37.08%-29.19% 16.12B
+0.24%+5.98%+23.45%+184.72% 13.64B
+5.51%+22.37%+171.85%+333.54% 14.8B
+1.83%+4.58%+77.42%+132.45% 12.16B
-2.37%+6.47%+157.84%+161.16% 11.85B
Average +0.25%+6.15%+68.82%+156.10% 25.17B
Weighted average by Cap. +1.20%+5.02%+65.91%+142.28%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.06 0.1 6.91 0.11 0.71 0.28 3.41 0.27 0.27 11.88 0.14 0.12 0.11 0.1 0.19 12.8 0.2 1.31 0.51 6.32 0.51 0.5 22
Net income -3.1M -2.72M -2.51M -2.34M -4.41M -294M -4.49M -30.09M -11.68M -145M -11.67M -11.4M -505M -18.47M -16.17M -14.93M -13.92M -26.24M -1.75B -26.71M -179M -69.52M -862M -69.41M -67.86M -3B
Net Debt 7.1M 6.21M 5.73M 5.35M 10.08M 671M 10.26M 68.77M 26.7M 331M 26.66M 26.06M 1.15B 7.15M 6.26M 5.78M 5.39M 10.16M 676M 10.34M 69.33M 26.92M 334M 26.87M 26.27M 1.16B
Logo Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-